June 14 (Reuters) - Actinogen Medical Ltd (ACW) :
- ACTINOGEN ANNOUNCES PHASE 2 TRIALS IN ALZHEIMER'S DISEASE AND DEPRESSION
- ACTINOGEN MEDICAL LTD - S EXPANDING ITS UPCOMING CLINICAL TRIAL PROGRAM TO INCLUDE A PHASE 2 TRIAL IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- ACTINOGEN MEDICAL LTD - MDD PHASE 2 TRIAL RESULTS ARE EXPECTED IN LATE 2023, OR 2024
- ACTINOGEN MEDICAL LTD - ALZHEIMER'S DISEASE (AD) XANAMIA PART B PHASE 2 TRIAL RESULTS ARE EXPECTED IN 2024
News: ACW Actinogen Announces Phase 2 Trials In Alzheimer's Disease And Depression
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.9¢ |
Change
0.002(7.41%) |
Mkt cap ! $92.08M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.0¢ | 2.9¢ | $290.7K | 9.832M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1059535 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 3159535 | 10 |
View Market Depth
| Last trade - 15.48pm 15/09/2025 (20 minute delay) ? |
| ACW (ASX) Chart |